108 related articles for article (PubMed ID: 28936999)
1. Non-adherence to CML therapy and its clinical implications in India.
Menon H
Natl Med J India; 2017; 30(3):142-147. PubMed ID: 28936999
[TBL] [Abstract][Full Text] [Related]
2. Adherence to BCR-ABL inhibitors: issues for CML therapy.
Jabbour E; Saglio G; Radich J; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):223-9. PubMed ID: 22633166
[TBL] [Abstract][Full Text] [Related]
3. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
4. Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia.
Pinilla-Ibarz J; Sweet K; Emole J; Fradley M
Anticancer Res; 2015 Dec; 35(12):6355-64. PubMed ID: 26637844
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of simultaneous bone marrow cytogenetic and peripheral blood molecular responses in chronic myeloid leukemia].
Lai Y; Qin Y; Huang X; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):104-8. PubMed ID: 24606648
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
7. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.
Luatti S; Baldazzi C; Marzocchi G; Ameli G; Bochicchio MT; Soverini S; Castagnetti F; Tiribelli M; Gugliotta G; Martinelli G; Baccarani M; Cavo M; Rosti G; Testoni N
Oncotarget; 2017 May; 8(18):29906-29913. PubMed ID: 28404889
[TBL] [Abstract][Full Text] [Related]
8. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.
Carneiro BA; Kaplan JB; Giles FJ
Expert Rev Hematol; 2015 Aug; 8(4):457-79. PubMed ID: 25938861
[TBL] [Abstract][Full Text] [Related]
10. When to Stop TKIs in Patients with Chronic Myeloid Leukemia and How to Follow Them Subsequently.
Cerveira N; Bizarro S; Teixeira MR; Mariz JM
Curr Treat Options Oncol; 2021 Apr; 22(6):49. PubMed ID: 33866455
[TBL] [Abstract][Full Text] [Related]
11. [The importance of taking late cardiovascular toxicity induced by TKI into consideration in patients with CML].
Takahashi N
Rinsho Ketsueki; 2016; 57(10):1956-1961. PubMed ID: 27725593
[TBL] [Abstract][Full Text] [Related]
12. The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
Wang J; Hu J; Jin Z; Wan H
Leuk Res; 2016 Aug; 47():32-40. PubMed ID: 27244255
[TBL] [Abstract][Full Text] [Related]
13. Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.
Noens L; Hensen M; Kucmin-Bemelmans I; Lofgren C; Gilloteau I; Vrijens B
Haematologica; 2014 Mar; 99(3):437-47. PubMed ID: 24598855
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
15. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
[TBL] [Abstract][Full Text] [Related]
16. Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission.
Erba HP
Am J Hematol; 2015 Mar; 90(3):242-9. PubMed ID: 25410137
[TBL] [Abstract][Full Text] [Related]
17. Molecular Detection of BCR-ABL in Chronic Myeloid Leukemia.
Qin YZ; Huang XJ
Methods Mol Biol; 2016; 1465():1-15. PubMed ID: 27581134
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
Yang K; Fu LW
Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000
[TBL] [Abstract][Full Text] [Related]
19. Bcr-Abl tyrosine kinase inhibitors: a patent review.
Desogus A; Schenone S; Brullo C; Tintori C; Musumeci F
Expert Opin Ther Pat; 2015 Apr; 25(4):397-412. PubMed ID: 25656651
[TBL] [Abstract][Full Text] [Related]
20. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]